Trial Profile
A Single Arm, Phase II Study of TNFerade Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2012
Price :
$35
*
At a glance
- Drugs Golnerminogene pradenovec (Primary) ; Cisplatin; Fluorouracil
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Sponsors GenVec
- 26 Apr 2012 Results have been reported in Gastrointestinal Endoscopy.
- 11 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2010 New trial record.